Lymphoma in the news: Exercise after completion of cancer treatment improves quality of life

By Peter Martin, MD

A recently published meta-analysis focused on the effects of physical activity in adults who had completed their cancer therapy (click here to read the abstract). Fong and colleagues compiled data from 34 randomized studies that assigned participants to either exercise or no exercise. Most of the studies evaluated aerobic exercise, and the average duration of activity was 13 weeks. Not surprisingly, participants randomized to exercise experienced significant improvements in body mass index, weight, and power output among other measures. Importantly, they also experienced significant gains in quality of life and other psychological outcomes (e.g., fatigue, depression).

A meta-analysis is a study that combines results from multiple related studies to derive a more powerful estimate of a true effect (click here to read more about meta-analyses). Although meta-analyses are often derided and are subject to various forms of bias, a well-performed meta-analysis is one of the most powerful methods of controlling for variation between studies and determining a true effect size in a population.

The results of this meta-analysis strongly suggest that patients who have completed cancer therapy can benefit from an exercise program. Moreover, it behooves oncologists to discuss the potential role of an exercise program with their patients. Patients should be encouraged to discuss the potential role of exercise with the oncologists and primary care physicians.

Research Leads to Cures: Weill Cornell Medical College

Follicular Lymphoma Clinical Trial

Combination Veltuzumab (Anti-CD20) and Fractionated 90Y- Epratuzumab (Anti-CD22) Radioimmunotherapy in Patients with Follicular Lymphoma

Update: this study is closed to enrollment. 

Monoclonal antibodies can fight lymphoma by binding to proteins expressed on lymphoma cells and either directly killing or inducing the immune system to kill the tumor cells.

With radioimmunotherapy, the antibody is labeled with a radioactive molecule, allowing directed delivery of radiation to the lymphoma.  Radioimmunotherapy is effective in follicular lymphoma, but immune reactions against the radiolabeled antibody have limited the utility of this approach.

In this study, we are evaluating the combination of an unlabeled antibody to one lymphoma-associated protein (CD20) with a radio-labeled antibody to a different lymphoma-associated protein (CD22), in hopes of improving responses. The antibodies are modified to minimize immune responses, and both antibodies will be given in repeated doses in order to increase the total amount of drug administered while limiting side effects.

Eligibility:

  • Follicular lymphoma
  • No more than 2 prior systemic treatments for non-Hodgkin’s lymphoma
  • Detailed eligibility discussed when you contact the study team

For more information, contact June Greenberg, RN at (212) 746-2651 or jdg2002@med.cornell.edu.

Click here to view all lymphoma clinical trials at Weill Cornell Medical Center.